Investing

Akero Therapeutics : AKRO

AKRO

Stock Data

$54.65

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Akero Therapeutics Inc is a biotechnology firm focused on creating treatments for serious metabolic diseases, with a spotlight on metabolic dysfunction-associated steatohepatitis (MASH). Their leading product, efruxifermin, is advancing through Phase 3 clinical trials, aiming to regulate metabolism and protect against cellular stress. Originating as Pippin Pharmaceuticals and rebranded in 2018, Akero has partnered with Amgen Inc. for the development and distribution of its treatments. The company is based in South San Francisco, California, and was established in 2017.

All Akero Therapeutics Articles

2 Articles

Trey Thoelcke | Apr 2, 2025 at 8:45 AM EDT

Insiders Are Loving These 5 Tech and Biotech Stocks

Insiders have lately been showing their love for these three biotech stocks, two tech stocks, and a utility stock with…

Trey Thoelcke | Dec 14, 2023 at 8:50 AM EST

What Has Insiders Eyeing This Biotech Stock

A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider…